Yanni Hao

2.0k total citations
89 papers, 1.5k citations indexed

About

Yanni Hao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Yanni Hao has authored 89 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 21 papers in Economics and Econometrics. Recurrent topics in Yanni Hao's work include Advanced Breast Cancer Therapies (25 papers), Cancer Treatment and Pharmacology (25 papers) and Health Systems, Economic Evaluations, Quality of Life (14 papers). Yanni Hao is often cited by papers focused on Advanced Breast Cancer Therapies (25 papers), Cancer Treatment and Pharmacology (25 papers) and Health Systems, Economic Evaluations, Quality of Life (14 papers). Yanni Hao collaborates with scholars based in United States, China and United Kingdom. Yanni Hao's co-authors include Xiaoling Shen, Zaiquan Dong, Karim Fizazi, Thian Kheoh, Arturo Molina, Christopher J. Logothetis, Paul N. Mainwaring, Dennis D. Gagnon, Howard I. Scher and Johann S. de Bono and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Yanni Hao

86 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yanni Hao United States	19	630	440	306	251	217	89	1.5k
Thenappan Chandrasekar United States	22	1.0k 1.7×	407 0.9×	460 1.5×	305 1.2×	198 0.9×	130	1.7k
Paul Craft Australia	23	278 0.4×	653 1.5×	333 1.1×	377 1.5×	135 0.6×	43	1.6k
Maysa Al‐Hussaini Jordan	21	369 0.6×	363 0.8×	395 1.3×	131 0.5×	141 0.6×	173	1.9k
Claire L. Vale United Kingdom	25	1.3k 2.0×	996 2.3×	508 1.7×	393 1.6×	358 1.6×	56	4.4k
Neil E. Martin United States	36	1.8k 2.9×	1.4k 3.3×	388 1.3×	373 1.5×	344 1.6×	165	4.0k
Carlos H. Bárcenas United States	26	327 0.5×	1.0k 2.3×	268 0.9×	767 3.1×	145 0.7×	106	2.1k
Jean‐Emmanuel Bibault France	25	526 0.8×	363 0.8×	140 0.5×	105 0.4×	921 4.2×	100	2.1k
Yu Cheng China	23	259 0.4×	393 0.9×	254 0.8×	124 0.5×	71 0.3×	73	1.3k
John H. Fetting United States	28	564 0.9×	1.6k 3.7×	522 1.7×	693 2.8×	112 0.5×	73	3.2k
Andrea Eberle Germany	28	424 0.7×	1.1k 2.5×	916 3.0×	124 0.5×	59 0.3×	73	2.7k

Countries citing papers authored by Yanni Hao

Since Specialization

Citations

This map shows the geographic impact of Yanni Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanni Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanni Hao more than expected).

Fields of papers citing papers by Yanni Hao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanni Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanni Hao. The network helps show where Yanni Hao may publish in the future.

Co-authorship network of co-authors of Yanni Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Yanni Hao. A scholar is included among the top collaborators of Yanni Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanni Hao. Yanni Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Mingqian, Deng Wang, Jie Zeng, et al.. (2025). Redox Shuttle-Stabilized Tin–Lead Perovskites for All-Perovskite Tandem Solar Cells. ACS Energy Letters. 10(10). 4749–4757.

Ma, Xiaolan, Ying Zhang, Pengju Tan, et al.. (2025). Alleviating trade‐off between responsivity and response speed of Ga₂O₃ solar‐blind photodetector via modulation of carrier redistribution and extraction accessibility. InfoMat. 7(9). 7 indexed citations

Dong, Zaiquan, Ke Han, Xiaoling Shen, et al.. (2024). Core antibiotic resistance genes mediate gut microbiota to intervene in the treatment of major depressive disorder. Journal of Affective Disorders. 363. 507–519. 2 indexed citations

Hao, Yanni. (2024). The Causes and Countermeasures of Juvenile Delinquency Motivation. Journal of Education Humanities and Social Sciences. 40. 81–85.

Jiao, Jian, et al.. (2023). Factors associated with medication interruption among outpatients with severe mental illness exposed to COVID-19. Frontiers in Public Health. 11. 1086863–1086863.

Dong, Zaiquan, et al.. (2022). Plasma levels of interleukin‐8 and response to paroxetine in patients with major depressive disorder. Human Psychopharmacology Clinical and Experimental. 37(6). e2855–e2855. 1 indexed citations

Dong, Zaiquan, Jing Ma, Yanni Hao, et al.. (2020). The social psychological impact of the COVID-19 pandemic on medical staff in China: A cross-sectional study. European Psychiatry. 63(1). e65–e65. 105 indexed citations

Hao, Yanni, Lamis Eldjerou, Hongbo Yang, & Cynthia Z. Qi. (2017). Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. Blood. 130. 609–609. 10 indexed citations

Snider, Julia Thornton, Yanni Hao, Pinar Karaca‐Mandic, et al.. (2017). The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom. Blood. 130. 1330–1330. 4 indexed citations

10.

Li, Nanxin, et al.. (2016). Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. Journal of Medical Economics. 19(4). 414–423. 4 indexed citations

11.

Hao, Yanni, et al.. (2016). Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Advances in Therapy. 33(6). 983–997. 9 indexed citations

12.

Li, Nanxin, et al.. (2016). Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2− mBC Patients With Multiple Metastatic Sites. Clinical Therapeutics. 38(4). 905–917. 2 indexed citations

13.

Hao, Yanni, et al.. (2016). Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Value in Health. 19(3). A145–A145. 1 indexed citations

14.

Engel-Nitz, Nicole, et al.. (2015). Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2 ^- metastatic breast cancer. Journal of Comparative Effectiveness Research. 4(4). 303–314. 6 indexed citations

15.

Li, Nanxin, Yanni Hao, Jipan Xie, et al.. (2015). Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. Current Medical Research and Opinion. 31(8). 1573–1582. 4 indexed citations

16.

Li, Nanxin, et al.. (2015). Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Current Medical Research and Opinion. 32(2). 385–394. 8 indexed citations

17.

Hao, Yanni, et al.. (2015). Comparative effectiveness of everolimus vs. fulvestrant monotherapy among postmenopausal women with hr+/her2- metastatic breast cancer. Value in Health. 18(3). A192–A192. 1 indexed citations

18.

Lin, Peggy L., Yanni Hao, Jipan Xie, et al.. (2015). Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey. Cancer Medicine. 5(2). 209–220. 11 indexed citations

19.

Lang, Kathleen, et al.. (2014). Treatment patterns among elderly patients with stage IV breast cancer treated with HER-2-targeted therapy. Journal of Comparative Effectiveness Research. 3(5). 481–490. 3 indexed citations

20.

Macalalad, Alexander R., Yanni Hao, Peggy L. Lin, et al.. (2014). Treatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010). Current Medical Research and Opinion. 31(2). 263–273. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact